Core Laboratories/$CLB
CLB falls after reporting Q2 revenue flat year-over-year and issuing Q3 guidance calling for essentially flat sequential revenue, which disappointed investors.
9 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Core Laboratories
Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.
Ticker
$CLB
Sector
Primary listing
NYSE
Industry
Energy Equipment and Services
Headquarters
Employees
3,400
Website
CLB Metrics
BasicAdvanced
$626M
21.54
$0.62
1.41
$0.04
0.30%
Price and volume
Market cap
$626M
Beta
1.41
52-week high
$25.13
52-week low
$10.14
Average daily volume
557K
Dividend rate
$0.04
Financial strength
Current ratio
2.269
Quick ratio
1.385
Long term debt to equity
62.488
Total debt to equity
66.793
Dividend payout ratio (TTM)
6.33%
Interest coverage (TTM)
4.27%
Profitability
EBITDA (TTM)
61.956
Gross margin (TTM)
19.56%
Net profit margin (TTM)
5.73%
Operating margin (TTM)
9.13%
Effective tax rate (TTM)
29.14%
Revenue per employee (TTM)
$150,000
Management effectiveness
Return on assets (TTM)
4.92%
Return on equity (TTM)
11.78%
Valuation
Price to earnings (TTM)
21.538
Price to revenue (TTM)
1.209
Price to book
2.37
Price to tangible book (TTM)
11.32
Price to free cash flow (TTM)
15.917
Free cash flow yield (TTM)
6.28%
Free cash flow per share (TTM)
83.93%
Dividend yield (TTM)
0.30%
Forward dividend yield
0.30%
Growth
Revenue change (TTM)
0.70%
Earnings per share change (TTM)
23.99%
3-year revenue growth (CAGR)
2.58%
10-year revenue growth (CAGR)
-6.11%
3-year earnings per share growth (CAGR)
50.72%
10-year earnings per share growth (CAGR)
-18.06%
10-year dividend per share growth (CAGR)
-32.71%
What the Analysts think about CLB
Analyst ratings (Buy, Hold, Sell) for Core Laboratories stock.
Bulls say / Bears say
Core Laboratories achieved a significant reduction in net debt by $42 million in 2024, lowering the leverage ratio to 1.31, the lowest in over eight years, indicating improved financial health and potential for future growth. (prnewswire.com)
The company reported a 200% year-over-year improvement in free cash flow for 2024, reaching $43.4 million, reflecting enhanced profitability and efficient working capital management. (prnewswire.com)
Core Laboratories expanded its proprietary HELIOS™ product line in 2023, offering advanced solutions for plug and abandonment operations, which could drive future revenue growth. (prnewswire.com)
The company's Production Enhancement segment experienced a 7% sequential revenue decline in Q4 2024, indicating potential challenges in maintaining consistent growth. (nasdaq.com)
Geopolitical factors and sanctions have produced headwinds to revenue growth and operating margins for the Reservoir Description segment, potentially impacting future performance. (nasdaq.com)
Core Laboratories' operating income decreased by 15.3% in Q2 2024 compared to the same quarter in 2023, suggesting potential profitability concerns. (apextraderfunding.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
CLB Financial Performance
Revenues and expenses
CLB Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Aug4
Core Laboratories
Dividend·Ex-dividend
Aug25
Core Laboratories
Dividend·Payment
$0.01Per share
FAQs
What’s the current market cap for Core Laboratories stock?
Core Laboratories (CLB) has a market cap of $626M as of July 26, 2025.
What is the P/E ratio for Core Laboratories stock?
The price to earnings (P/E) ratio for Core Laboratories (CLB) stock is 21.54 as of July 26, 2025.
Does Core Laboratories stock pay dividends?
Yes, the Core Laboratories (CLB) stock pays dividends to shareholders. As of July 26, 2025, the dividend rate is $0.04 and the yield is 0.3%. Core Laboratories has a payout ratio of 6.33% on a trailing twelve-month basis.
When is the next Core Laboratories dividend payment date?
The next Core Laboratories (CLB) dividend payment is scheduled for August 25, 2025.
What is the beta indicator for Core Laboratories?
Core Laboratories (CLB) has a beta rating of 1.41. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.